CRF01_AE: Do we need a customized CCR5 antagonist treatment recommendation? Nico Pfeifer Max Planck Insitute for Informatics
HIV coreceptor usage
HIV coreceptor usage
HIV coreceptor usage
HIV coreceptor usage
CRF01_AE update • Recent papers report high proportions of X4- capable CRF01_AE infected patients – Mulinge et al. 2013, PLoS ONE – Wai-Chi To et al. 2013, AIDS Res Hum Retroviruses. • Overestimation of X4-capable or other reasons?
Could be confounded http://www.hivviralload.com/blog/2008/11/25/the-hiv-subtype-picture.html
Genetic tropism test Adapted from: T. Lengauer, N. Pfeifer, and R. Kaiser Personalized HIV therapy to control drug resistance Drug Discovery Today: Technologies 2014, 11, pp 57-64
Genetic tropism test Adapted from: T. Lengauer, N. Pfeifer, and R. Kaiser Personalized HIV therapy to control drug resistance Drug Discovery Today: Technologies 2014, 11, pp 57-64
Genetic tropism test Standard geno2pheno[coreceptor] version [1] New geno2pheno-C_NGS-Sanger version [2] 1. Lengauer et al. 2007, Nature Biotechnol. 2. Pfeifer and Lengauer 2012, Bioinformatics
Geno2pheno-C_NGS-Sanger Training Prediction Pfeifer and Lengauer 2012, Bioinformatics
Could be improved? • Collaboration with Nagoya Medical Center (Japan) and Klimkait et al. (InPheno, Uni Basel) – 297 V3 loop sequences of CRF01_AE – Discordance between standard geno2pheno[coreceptor] [1] and new version [2] for certain cases (X4-capable / R5) – Selected 21 samples with largest discordance as well as 5 samples with X4 agreement (control) – PhenXR phenotypes measured in Basel 1. Lengauer et al. 2007, Nature Biotechnol. 2. Pfeifer and Lengauer 2012, Bioinformatics
Current results • 17 samples successfully phenotyped – 14/15 calls with X4-capable / R5 (old / new G2P) were phenotyped as R5 (the other one was mixed-dual according to PhenXR) – Only 2 of the X4/X4 calls could be phenotyped (both R5 according to PhenXR) • Conclusions – It seems as if calling CRF01_AEs R5 when new tool confidently calls it R5 is better than using the old calls – Need more samples for intermediate range
Thanks to … Thomas Lengauer Rolf Kaiser Thomas Klimkait Séverine Louvel Wataru Sugiura Masakazu Matsuda Yoshiyuki Yokomaku
Thanks to … Thomas Lengauer Rolf Kaiser Thomas Klimkait Séverine Louvel Wataru Sugiura Masakazu Matsuda Yoshiyuki Yokomaku
CCR5 Antagonist CCR5 Antagonist Drug Development Issues Drug Development
Alcohol Antagonists 1 What is an alcohol antagonist? An alcohol antagonist
Recommendations for determining HIV-1 coreceptor usage CCR5 antagonists proved
Bonn, 24.04.2009 Bonn, 24.04.2009 Clinical Use of Clinical Use of CCR5
AREVIR-Meeting, Kln 12.04.2013 CCR5 longitudinal was tun bei
AREVIR 11.04.2008 CCR5 Antagonists Antagonists CCR5 In Clinical Clinical
Treatment of HIV and EBV associated lymphoma by allogenic CCR5 32 blood stem
What is Customized Employment? Laura Owens, Ph.D., CESP September 12, 2018
P he hen G en ene P 2 Y 12 12 T es est 1 CLOPIDOGREL A second-generation
11/13/2012 Journal The Disruptive Effects of the CB 1 Receptor Antagonist
Calculation of the Minimum Anticipated Biological Effect Level (MABEL) and 1
Independent Novel Project: Google Slides Document Criteria Students will read
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation
The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial
DISCLOSURE No disclosures, financial, or otherwise to declare ANATOMY
5/4/2016 Disclosure Information PT2385: HIF 2 Antagonist for the Treatment
OPIOID OVERDOSE PREVENTION Guidance for Implementing Overdose Prevention in
We are a responsibly - driven company focused on achieving the most
Case Presentation Case Presentation 79 year old gentleman underwent CABG 10
Intracoronary Compared with Intravenous Bolus Abciximab Application During
Dr. Sudarshan subedi et al., IJSIT, 2018, 7(2), 205-210 CASE PRESENTATION OF
Supraventricular tachycardia from a left bundle branch block-An unusual